Home > Media News > Sellas' vaccine extends survival in blood cancer trial

Sellas' vaccine extends survival in blood cancer trial
17 Nov, 2026 / 05:14 PM / Sellas

57 Views

Nov 17 (Reuters) - Drug developer Sellas Life Sciences (SLS.O) said on Tuesday its experimental vaccine for a type of blood cancer helped patients live significantly longer in a late-stage trial.

The vaccine, ‌called galinpepimut-S or GPS, was tested in patients with acute myeloid leukemia (AML), who were in remission after cancer therapy but were unable to receive a bone marrow or stem cell transplant.

AML is an aggressive cancer of the blood and bone marrow, and patients whose disease returns ⁠after treatment often face limited care options.

GPS cut the risk of death by 41% compared to best available treatment in the study involving 126 patients, Sellas said. Patients treated with the vaccine lived for a median of 24 months, compared to 14.7 months for those in the control group.

Sellas said the vaccine was generally well tolerated and raised no new safety concerns. Most side effects were mild to moderate, and the most common was a ‌reaction ⁠at the injection site.

The vaccine works by training the body's immune system to find and attack leftover leukemia cells that carry a protein called WT1.

"The magnitude of the survival benefit observed with our investigational GPS immunotherapeutic cancer vaccine represents a ⁠defining milestone for Sellas," said CEO Angelos Stergiou.

According to the American Cancer Society, about 22,720 people will be diagnosed with AML and about 11,500 are expected to die ⁠from the disease in 2026. AML accounts for 1 out of 3 leukemias in adults.

Sellas plans to meet with the US Food and Drug ⁠Administration to discuss a regulatory path, aiming to submit an application for approval in the first half of 2027. Its shares were halted in premarket trading.